Skip to main content

Drug Interactions between oxymorphone and SuTan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexchlorpheniramine oxyMORphone

Applies to: SuTan (dexchlorpheniramine / pseudoephedrine) and oxymorphone

Using dexchlorpheniramine together with oxyMORphone may increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food/lifestyle interactions

Major

oxyMORphone food/lifestyle

Applies to: oxymorphone

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Consumption of alcohol while taking immediate- or extended-release formulations of oxymorphone may result in high systemic levels of oxymorphone and fatal overdose even in opioid-tolerant patients. Additionally, alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxymorphone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

ADJUST DOSING INTERVAL: After oral dosing with 40 mg of oxymorphone hydrochloride in healthy volunteers under fasting conditions or with a high-fat meal, the maximum plasma concentration (Cmax) and systemic exposure (AUC) of oxymorphone were increased by approximately 38% in fed subjects compared to fasted subjects.

MANAGEMENT: Patients taking opioid analgesics including oxymorphone should not consume alcohol or use medications that contain alcohol. Modified and/or extended-release oxymorphone formulations must also be swallowed whole and not crushed, chewed or divided. In addition, oxymorphone should be administered on an empty stomach, at least 1 hour before or 2 hours after food intake.

Moderate

dexchlorpheniramine food/lifestyle

Applies to: SuTan (dexchlorpheniramine / pseudoephedrine)

Alcohol can increase the nervous system side effects of dexchlorpheniramine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with dexchlorpheniramine. Do not use more than the recommended dose of dexchlorpheniramine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Moderate

pseudoephedrine food/lifestyle

Applies to: SuTan (dexchlorpheniramine / pseudoephedrine)

Both pseudoephedrine and caffeine can increase blood pressure and heart rate, and combining them may enhance these effects. Talk to your doctor before using these medications, especially if you have a history of high blood pressure or heart disease. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.